Bayer’s Vividion Signs US$930 M Cancer Collaboration with Tavros Therapeutics

By Lucy Haggerty

Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)

Published: 15 Oct-2022

DOI: 10.3833/pdr.v2022.i10.2735     ISSN: 1756-7874

Section: Research & Development



On the hunt for undruggable targets, Vividion Therapeutics has entered into a collaboration with Tavros Therapeutics to identify four cancer targets, with an option to pursue up to five more...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details